Ethan Cancer Research Journal
Volume 1 Issue 1 February 2024
ISSN: Pending…

UNCOVERING INTEGRATIVE STRATEGIES: THE PROMISE OF EGCG IN FIGHTING PROSTATE CANCER

Alexander Müller and Sophie Schmidt
Department of Biology, Ludwig Maximilian University of Munich, Munich, Germany

Abstract: Prostate cancer is the most common cancer in males and one of many types of malignancies that are said to be prevented by drinking green tea and Epigallocatechin-3-gallate (EGCG) intervention. However, epidemiological studies have produced conflicting results regarding the anti-cancer effects of EGCG. In recent years, numerous researchers have demonstrated the effectiveness and safety of green tea polyphenols, including EGCG alone and in combination therapies, through *in vivo* and *in vitro* studies. Nevertheless, the molecular mechanisms underlying the anticancer potential of EGCG remain poorly understood. To evaluate the prevention and treatment of prostate cancer, it is critical to have a better understanding of the precise mode of action of EGCG against the growth and progression of prostate cancer. With a focus on the molecular mechanisms of action of EGCG, such as influencing tumour growth, apoptosis, androgen receptor signaling, cell cycle, and various malignant behaviors, we present information regarding the anti-cancer effects of EGCG in the prevention and treatment of prostate cancer in this review.
Keywords: EGCG, Prostate Cancer, Signaling Pathways, Clinical trials.

INTRODUCTION

With 12,76,106 new cases and 3,58,989 deaths (3.8% of all deaths from cancer in men), Prostate cancer (PCa) is the second most common malignancy in men worldwide (after lung cancer)[1]. According to Rawla et al[2], PCa incidence and mortality are both correlated with ageing globally, with an average age of 66 at diagnosis. Due to population growth and ageing, it is predicted that there will be almost 2.3 million cases of PCa globally and 7,40,000 deaths by 2040[3]. The well-known risk factors for PCa are age, race, and a family history of the disease[4]. There are numerous reports that claim low plasma-selenium and -tocopherol concentrations and high calcium intake in the diet increase the risk of PCa[5]. Androgens are necessary for the growth and development of the prostate gland, and it has long been believed that high levels of them are a major factor in the development of PCa[6,7]. According to recent studies, the majority of prostate tumours respond to androgen deprivation therapy until the point at which they develop an androgen-independent growth mechanism[8,9].

Multiple strategies have been proposed so far to contain the growth and progression of PCa. One such strategy is the use of naturally occurring compounds of plant origin. Ayurveda, Homoeopathy, and Unani are just a few of the indigenous medical systems that heavily rely on medicinal plants, including tea plants, which are grown in places like China and India[10]. Researchers and health professionals have begun to pay close attention to tea (*Camellia sinensis*), which is the second most consumed beverage after water worldwide[11-14]. There are many different types of tea, but green and white tea are thought to be the healthiest because they contain the highest concentrations of tea catechins, which make up 30–40% of their dry weight along with only trace amounts of flavonoids. EGCG is well known to have anti-cancer, anti-inflammatory, and anti-aging properties. Epigallocatechin-3-gallate (EGCG), epigallocatechin (EGC), epicatechin gallate (ECG), and catechin are the four main catechins present in tea[15,16]. According to Stewart et al[17], catechin and EGCG are the primary antioxidants in green tea, accounting for about 30% of its overall antioxidant capacity. Numerous health conditions, including cancer, have been studied in-depth using EGCG as a preventive and therapeutic agent[18-24]. The ability of EGCG to inhibit the growth of multiple malignant cells and to induce apoptosis has also been emphasized in many studies[24-29]. EGCG controls cancer via blocking of various signaling molecules/pathways like cell cycle regulation, JAK/STAT, MAPK, PI3K/AKT, Wnt and Notch[30], apoptotic pathway, and angiogenesis[31], which in

turn influence the molecular events that ultimately result in carcinogenesis. In this review, we will assess the findings derived from *in vitro, in vivo,* and clinical trials that have been carried out to examine the protective effects of EGCG against PCa. Furthermore, we will formulate research queries that could serve as a foundation for forthcoming investigations in this realm.

PROSTATE CANCER

Prostate intraepithelial neoplasia is the first stage of the malignant transformation of prostate cells, which then progresses to localized PCa, local invasive adenocarcinoma, distant metastasis, primarily to the lymph nodes or bone, and finally an androgen-independent phenotype[32]. The most well-known premalignant lesion and precursor to prostatic carcinoma is prostatic intraepithelial neoplasia. The progression of PCa results in progressive abnormalities of phenotype and genotype, indicating impairment in cell differentiation and regulatory control. The androgen receptor (AR) is a crucial transcription factor that triggers the tumorigenesis and progression of androgen dependent PCa[33,34] (Figure 1). Hence, the



Figure 1. Normal Prostrate cancer growth and development and intervention by EGCG: testosterone after entering the prostate cell is converted into Dihydrotestosterone (DHT) by 5α-reductase. DHT binds to androgen receptor (AR) and induces its phosphorylation and dimerization. These AR dimers enter the nucleus and attaches to androgen response elements (ARE) along with other coactivators, thereby leading to the activation of target genes. This signals the upregulation of cell proliferation, mitochondrial dysfunction and downregulation of Apoptosis and thus resulting in enhanced cell growth and cell survival. On the other hand, EGCG may prevent prostate cancer by modulating the above events. (Modified from Feldman and Feldman[48]).

initial phase of treatment for androgen-dependent PCa involves androgen depletion therapy. However, these cancerous cells eventually get transformed into the currently incurable androgen-independent PCa (AIPC)[35,36]. Androgen deprivation therapy has been found to be futile at this point since the cancerous cells are now hormone-insensitive and capable of growing without androgen, leading to metastasis[30,37,38]. A number of investigations have demonstrated that aberrant AR expression and persistent AR signaling are important contributors to the development of AIPC[39,40]. Even in the presence of low testosterone levels and/or an absence of androgens, the enhancement of AR-mediated signals in AIPC cells leads to increased cell proliferation[1,41,42] (Figure 2). Prostate intracrine androgen biosynthesis, AR



Figure 2. Schematic representation of possible pathways for development of androgen independent PCa (AIPC): (i) amplification of AR receptors mostly by enhanced gene expression and increased coactivators are dependent on both androgen and androgen receptors, (ii) promiscous and outlaw pathways are independent of androgens but depend upon AR, (iii) by pass pathway and prostate cancer stem cell which continuously supply new cancer cell population are independent of both androgen and AR[49].

amplification, mutation, AR-splice variants, modification of AR co-regulators, modulation of oncogenes and tumour suppressor genes, and differentiation of neuroendocrine cells are the mechanisms that contribute to the progression of AIPC[38]. The first five pathways depend on ongoing AR signaling activation and are, therefore, AR-dependent. The last two pathways are not dependent on AR signalling[43,44] (Figure 2). Both *in vitro* and *in vivo* studies of AIPC have linked AR amplification and overexpression to the disease[43,45]. Even in the presence of low levels of circulating androgen, aberrant gene amplification may result in the overexpression of AR and subsequently enhance AR-androgen ligand binding[39]. Additionally, AR mutations may also be present in PCa cells. These mutations change the AR ligand-binding domain, increasing the binding specificity to other endogenous steroid ligands (such as progesterone, corticosteroids, and oestrogen)[46], thereby increasing AR transactivation activity. The lack of a ligand-binding domain in tumor cells allows them to become constitutively active, bypassing the need for androgens[18]. The overall AR activation in AIPC may also be influenced by the coactivator/corepressor ratio. In AIPC cells, co-activators are overexpressed, and they regulate AR activity to help the cells become androgen-independent[47]. Contrarily, it has been observed that the co-repressor proteins are down-regulated in AIPC, leading to an increase in AR-mediated transcriptional activity[43].

The development of treatment resistance and subsequent progression to AIPC were caused by the progression of PCa to neuroendocrine differentiation of PCa cells (NEPC)[48-50]. This pathway is classified as an AR-independent pathway, in contrast to the previously discussed pathways. NEPC cells continuously secrete neuropeptides like serotonin and bombesin, which have paracrine effects on neighboring cells despite the absence of androgen. These neuropeptides increase the ability of PCa cells to proliferate, move, and spread[51]. Through the manipulation of the Bcl-2 oncogene and PTEN (phosphatase and tensin homologue deleted on chromosome-10) tumour suppressor genes, AIPC cells also acquire the capacity to endure androgen castration. PTEN controls the PI3 pathway's activity negatively, which is linked to cell migration, survival, and proliferation. The

downregulation of PTEN results in constitutive PI3 pathway activation, which in turn promotes the translocation of AR molecules and AR-mediated transcriptional activity[52].

EGCG AND PCA

Structure and Mode of Action of EGCG

EGCG is a key active tea ingredient with a variety of health advantages[42,43]. It is the ester of epigallocatechin and gallic acid and has a polyhydroxy structure that makes it highly hydrophilic and low in lipophilia. One bag of green tea is thought to contain 80–100 mg of polyphenols, of which 25–30 mg come from EGCG. According to Botten et al[53], the structural components of EGCG include a benzenediol ring (A) attached to a tetrahydropyran moiety (B), a pyrogallol ring (C), and a galloyl group (D). The hydroxyl groups on the rings are thought to be responsible for their biological activity because they interact with other biological components through hydrogen bonds and electron transfer. These are the primary factors influencing the antioxidant activity of EGCG[45]. EGCG is water-soluble and is not impacted by high temperatures; exposure to conditions like boiling water cannot significantly affect the stability of the molecule[54]. The powerful antioxidant and chelating properties of EGCG make it useful for preventing a number of diseases linked to an increase in oxidative stress[13]. EGCG is considered the most effective modulator of prostate carcinogenesis[55-59]. EGCG has the potential to inhibit a variety of proteins linked to cancer, including the cyclin-dependent kinase inhibitor p27, Bcl-2, Bax, matrix metalloproteinases (MMP2 and MMP-9), androgen receptor, EGF receptor, and activator proteins-1[60]. Similarly, EGCG can inhibit PCa development by inducing apoptosis and inhibiting proteasome activity, B-alfa and p27 proteins as well[61-64] (Figure 3).



Figure 3. Structural composition of (−)-epigallocatechin gallate (EGCG).

Absorption, metabolism, and bioavailability of EGCG

Oral EGCG has been reported to be absorbed into the blood through the gastrointestinal tract to play its biological role[65]. It takes around 90 minutes for EGCG to reach its peak plasma level after oral consumption[66]. According to Hara et al[67], ECGC also interacts with saliva upon entering the mouth and some concentrations of EGCG in saliva have also been found after drinking tea. In the intestine, the metabolic interaction of EGCG with gut microbiota, its oxidation and efflux decrease the bioavailability of EGCG subsequently affecting its biological activity[68]. According to Nakagawa and Miyazawa[69] the maximum concentration of EGCG was 0.012% and 0.32% of ingested EGCG in fasted rat and human plasma, respectively, thereby demonstrating the poor bioavailability of EGCG. Studies have reported that the intestinal stability of EGCG is affected by change in temperature and intestinal pH. EGCG is prone to decomposition in intestinal pH conditions. According to Zagury et al[70], under simulated conditions of intestinal pH, the recovery rate of free EGCG was found to be less than 10%. Further, EGCG is subjected to action of gut microbiota. In a study, EGCG was reported to be hydrolyzed by gut microbiota

(such as *Enterobacter aerogenes*, *Raoultella planticola*, *Klebsiella pneumoniae* etc.) into EGC and gallic acid, and EGC was further degraded by cascade of conversions, thereby resulting in 5-(3,5-dihydroxyphenyl)-4-hydroxyvaleric acid as the main metabolite of EGCG which was found in rat cecal contents and feces[71].

According to Schantz et al[72] microbial esterase activity is presumably responsible for the cleavage of gallate moieties of EGCG during its passage through the small intestine. EGCG is also converted into metabolites via methylation, sulfation, and glucuronic acid through metabolic enzyme II of hepatic and intestinal cells[73]. Among these pathways, methylation is thought to be a significant metabolic pathway, producing important metabolites such as 4'-O-methyl-EGCG, 4',4'-dimethyl-EGCG-3'-glucuronate, 3',4'- or 3',5'-dimethyl-EGCG-4'-O-glucuronic acid[74]. Thus, the chemical instability decreases the absorption and bioavailability of EGCG. Furthermore, the poor permeability of intestinal EGCG also affects its bioavailability. Since specific receptors for the transport of EGCG are not found on the surface of intestinal epithelial cells, EGCG is mainly absorbed through passive diffusion including acellular and transcellular diffusion. Further, most of the absorbed EGCG is pumped back into the intestinal lumen through active transportation via efflux proteins[65]. The part of EGCG that enters the blood through intestinal absorption is circulated to other parts of the body. Some metabolic pathways of EGCG such as methylation, glucuronidation and sulfation, have also been reported to occur in blood. Among these, methylation considered the major metabolic pathway, results in formation of 4'-O-methyl-EGCG, 4',4'-dimethyl-EGCG-3'-glucuronate, 3',4'- or 3',5'-dimethyl-EGCG-4'-O-glucuronic acid[74]. The liver also causes acidification of EGCG and converts it into EGCG-4''-O-glucuronic acid complex. Additionally, the amount of EGCG that the liver removes from the blood is secreted into the bile. From the small intestine, a large amount of EGCG may remain unabsorbed or after enterohepatic recycling, is passed into the large intestine which is further extensively degraded by bacteria present in the colon. Catechins (EGCG, ECG, EC, EGC) incubated with human fecal suspension were metabolized to 3',4',5'-trihydroxyphenyl-γ-valerolactone, 3',4'- dihydroxyphenyl-γ-valerolactone, 3'-hydroxyphenyl-γ-valerolactone and other metabolites[75]. These metabolites further undergo side-chain shortening to produce C-6−C-1 phenolic and aromatic acids that enter the bloodstream and are excreted in urine[76].

Cancer preventive effects of EGCG

Numerous epidemiological studies have linked dietary habits to PCa risk. Because of their ancient traditional diets, Asian men have a low incidence of PCa[77,78]. Low fat, high fiber diets are common among Chinese and Japanese people, which may contribute to chemoprevention and the low incidence of cancer in these populations, including PCa[11,41,79-82]. According to another similar study[83], men who drank green tea five or more times per day had a 29% high negative correlation with PCa. Green tea catechins (GTC), including EGCG, may be able to inhibit cell division, cell cycle progression, and induce apoptosis through a variety of molecular mechanisms[57,84,85]. The chemopreventive and anticancer effects of EGCG against PCa have not yet produced conclusive results, despite epidemiological evidence to the contrary[86].

Cell line studies

It is challenging to ascertain how EGCG can lower the incidence of PCa due to the conflicting and unclear epidemiological evidences. Therefore, numerous studies have been conducted to determine the precise molecular mechanism by which EGCG inhibits the development and growth of PCa. In a series of studies conducted on different PCa cell lines, researchers have extensively investigated the effects of EGCG (Epigallocatechin gallate), a polyphenol found in green tea. The results from these studies collectively demonstrate the potential of EGCG as a promising therapeutic agent for PCa treatment. The findings of some studies suggest that EGCG has the potential to modulate cell cycle regulators, cell proliferation[87,88], vascular endothelial cadherin[89], and mitochondrial signal transduction pathways in PCa. Among these, the apoptotic pathway is found to be the main target of EGCG in PCa. Table 1 provides information

Table 1. Studies demonstrating how EGCG affects various molecules within prostate cancer cell models.

Cell line/model	Dose	Findings	Reference

DUPRO and 90	LNCaP cells	10µg/ml GTP, 20 µM EGCG	Reduced class I histone deacetylase (HDAC) activity /expression and EZH2 and H3K27me 3 levels in prostate cancer cells.	
LNCaP prostate cancer 91		2-4 mg/L (about 5-10µm) Cur, 1µM Arc and 40µM EGCG	In LNCaP cells both Arc and EGCG increased pro-apoptotic effect of Cur.	
DU145 cell line		EGCG (1.5-7.5µM) Radiotherapy and EGCG together	Reduced ionizing radiation induced apoptosis (P< .001), 1.5 -fold increase in Manganese superoxide dismutase levels.	92
(PC)3 Cells 30 and 100µg/ml PE (polyphenol)			Decreased cell viability and proliferation. Mitochondrial dysfunction and downregulation of Akt activation.	93
LNCaP cells 94		5-10µM curcumin 40µM EGCG	Improve synergistically in vitro antiproliferative by 40% in androgen sensitive LNCaP cells. It also enhanced cell apoptosis induction and cell cycle perturbation.	
PC-3 Cells		EGCG (10,20,40,80 µm) for 24 hour and performed 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide	80µM EGCG decreased cell viability. EGCG downregulated the expression of vascular endothelial cadherin	89
LNCaP cells and PC-3 Cells 81		10-80µg/ml of GTP for 24 hours	Dose dependent inhibition of class I HDAC enzyme activity and its protein expression.	
DU145 cells and RWPE-1 cells		10-50 µg/mL LEGCG on DU145 cells and 40-50µg/mL cells on RWPE-1 cells	A little higher inhibition rate on DU145 cells but exhibited high cytotoxicity on RWPE-1	46
DU-145 cells		EGCG (40µg/ml) 4 h treatment	Reduced cell number by 20% with 24 h and	96
PC-3 cells 97		80µmol/L Zn2+ and 80µmol/ L EGCG	Could induce apoptosis of PC-3 cells and cause sufficient damage to cells to rest in Necrosis.	
Human beings 98		Two 300mg green tea leaf derived extract Capsules (600mg/d EGCG)	Men at increased risk of prostate cancer sticked to lycopene and green tea diet and capsule intervention for 6 months with some side effects	
DU145 cells 33		100-200µM EGCG	Inhibition of TGF-α caused activation of erbB1 followed by inhibition of Shc activation without alteration in protein level.	
CWR22Rv1 86		0, 0.1, 1, 5, 10, or 50µM EGCG, genistein or quercetin	Inhibition ability of CWR22Rv1 cells to form colonies at doses >5µM whereas 5µM genistein produced affects not significantly different from vehicle treated control cells.	
PC-3 AP-1 Human PCa cells 99		EGCG (20 or 100 µmol/L) and SFN (25 µmol/L)	AP-1 activation attenuated and 100mg/kg SFN downregulated Nrf-2 dependent genes.	
LNCaP cells 100		20µM EGCG and DHT	It showed a similar viability as control cells without DHT treatment. It also inhibited growth to level similar to cells with no stimulation of androgen.	

PC3 cells	1 and 25μM EGCG	1μM EGCG sufficiently increased the proportion of apoptotic bodies and reduce cell survival.	101
DU-145 cells	5-40 μg/ml EGCG	Inhibited FCM- induced production of pro-MMP-2, and pro and active forms of MMP-9. Even 5μg/ml EGCG was able to inhibit synthesis of MMP-2 and -9	102
LNCaP cells and PC3 and DU145	EGCG on growth and (0-200μM) and on cell increase CaP cell lines	death (0-50μM) In dose dependent manner EGCG decreased proliferation of all CaP cancer cells with in apoptosis from 30 to50μM.	103

on the dose of EGCG and particular cell lines that were used in various studies. EGCG has been shown to inhibit the growth of PCa cells through various mechanisms. For instance, when DU145 cells were treated with Lipophilized EGCG, a derivative of EGCG, it resulted in a significant inhibition of cancer cell growth[46]. Another similar study showed the augmentation in growth inhibitory effects of EGCG on a variety of cancer cells when used in conjunction with ibuprofen[90-96].

In addition to inhibiting cancer cell growth, EGCG is also a promising candidate to induce apoptosis (programmed cell death) in PCa cells. A concurrent increase in apoptosis and decreased proliferation in all PCa cells upon treatment of LNCaP cells with EGCG has been revealed[97-103]. Moreover, a combination of EGCG with Arctigenin (Arc) and curcumin enhanced the anti-proliferative effect and increased apoptosis in LNCaP cells, suggesting a potential combinatorial approach for PCa treatment[91]. Similarly, a synergistic effect between EGCG and curcumin in inducing apoptosis and perturbing the cell cycle in androgen-sensitive LNCaP cells was also reported[94].

The benefits of EGCG are not restricted to a few cell lines; it also showed promising effects in several PCa cell types. In PC3 cells, EGCG and zinc were found to induce apoptosis, leading to cell damage and arrest in necrosis[97]. Additionally, EGCG treatment led to decreased cell viability and downregulated expression of Vascular Endothelial Cadherin, further indicating its potential for inhibiting cancer cell growth and impairing cell function[89]. In addition, three substances —EGCG, genistein, and quercetin — synergistically reduced the proliferation of CWR22Rv1 CaP cells, suggesting a potential combination therapy for PCa[87].

EGCG's actions on PCa cells extend beyond direct growth inhibition and apoptosis induction. In DU145 cells, EGCG, together with silymarin and genistein, was shown to inhibit mitogenic signaling pathways and cell cycle regulators, leading to the inhibition of TGFα-induced activation of erbB1 and Shc[33]. Treatment of DU145 cells with EGCG also inhibited the production and activation of certain matrix metalloproteinases (MMPs), further supporting its potential as an anti-cancer agent[102]. Furthermore, EGCG has been implicated in epigenetic regulation, offering new insights into its anti-proliferative mechanisms. Treatment of LNCaP cells with GTP (green tea polyphenol) resulted in the inhibition of class 1 HDAC enzyme activity and potentially affecting gene expression and cancer cell growth[81]. Moreover, GTP and EGCG treatment induced the expression of TIMP-3 mRNA and protein, reduced class I HDAC activity and expression, and lowered EZH2 and H3K27me 3 levels in PCa cells, suggesting an epigenetic basis for their effects[90].

Clinical trials

Numerous clinical trials are underway to analyze the beneficial effects of natural products such as catechins including EGCG in inhibiting the growth and development of PCa. For instance, a clinical trial was conducted on 26 men with positive prostate biopsies and scheduled for radical prostatectomy to analyze the protective efficacy of Polyphenon E (PolyE) in PCa patients[85]. The men were supplemented with daily doses of PolyE containing EGCG and other catechins. Their serum biomarkers including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF)-I, IGF binding protein-3 (IGFBP-3), and prostate-specific antigen (PSA) were analyzed before initiation of the drug study and on the day of prostatectomy in these men and a significant decrease in all these biomarkers with no elevation of liver enzymes was observed during the study. Further, decrease in HGF and VEGF was confirmed in prostate cancer-associated fibroblasts *in vitro*, thereby suggesting the potential role for PolyE in the treatment or prevention of prostate cancer. A similar

placebo-controlled, randomized clinical trial of PolyE, a proprietary mixture containing 400 mg EGCG, conducted on 97 men with high-grade prostatic intraepithelial neoplasia (HGPIN) and and/or atypical small acinar proliferation (ASAP) showed a decrease in serum prostate-specific antigen (PSA) on the PolyE arm. However, EGCG was accumulated in plasma and was well tolerated but did not reduce the likelihood of prostate cancer in men with baseline HGPIN or ASAP[104]. In similar lines, in clinical trials of PolyE performed on 97 men with HGPIN and ASAP, so as to analyse the safety of one-year administration of green tea catechins[105], the authors reported accumulation of EGCG in the plasma was well tolerated and did not produce treatment related adverse effects in men.

In another clinical trial by Lane et al[98], the dietary intervention in men at increased risk of PCa was analyzed through randomized Placebo-controlled trial of green tea catechins and lycopene. 569 men with PSA level of 2.0-2.95 ng/mL or 3.0-19.95 ng/mL with negative prostate biopsies were given daily green tea and lycopene: green tea drink (3 cups, unblinded) or capsules (blinded, 600 mg EGCG or placebo) and lycopene-rich foods (unblinded) or capsules (blinded, 15 mg lycopene or placebo) for 6 months. Mean lycopene was observed to be 1.28 times higher in the lycopene capsule group and 1.42 times higher in the lycopene-enriched diet group compared with placebo capsules. Also, EGCG was 10.7 nmol/L higher in the active capsule group and 20.0 nmol/L higher in the green tea drink group compared with placebo capsules. They further suggested the feasibility of a chemoprevention clinical trial.

Further some of the clinical trials have shown the modulation in the bioavailability of catechins when combined with other dietary components. The clinical trial in 31 men with prostate cancer demonstrated the enhanced bioavailability of GT polyphenols (GTPs) and reduced methylation activity with the chronic consumption of green tea extract (GTE) along with quercetin for four weeks before prostatectomy. 14-fold, 12-fold and 4.5-fold increase in quercetin was found in plasma, urine, and prostate tissue, respectively, in the GT + Q compared to the GT + placebo (PL)-group. Also, an increased plasma EGC was observed in the GT + Q in comparison to the GT + PL-group[106]. Wang et al[107], studied the metabolism and bioactivity of green tea polyphenols in men with clinically localized prostate cancer supplemented with green tea polyphenols for 3 to 6 weeks before undergoing radical prostatectomy. 4’’-O-methyl EGCG (4’’-MeEGCG) and EGCG were observed in comparable amounts, while as ECG was found in lower amounts in prostatectomy tissue. From 50% to 60% of both EGC and epicatechin were present in methylated form in the urine samples of men consuming green tea. Additionally, LNCaP prostate cancer cells incubated with EGCG, were able to methylate EGCG to 4’’-MeEGCG and there was significant decrease in the capacity of 4’’-MeEGCG to inhibit proliferation and NF-kappaB activation and induce apoptosis in LNCaP cells. Through these clinical trials, the authors suggested the modulation of preventive effects of EGCG based on the methylation status and genetic polymorphism of catechol O-methyl transferase.

CONCLUSIONS

While definitive conclusions about the precise molecular mechanisms by which EGCG operates in PCa are currently elusive, its pivotal role in influencing various molecular pathways, including apoptosis, the AKT pathway, and cell cycle regulation, remains indisputable. The challenge lies in effectively demonstrating EGCG’s anti-cancer efficacy in both *in vivo* models and human cancer cell lines, as the majority of the mentioned studies focus on cancer cell lines. Additionally, the potential benefits of combining EGCG with other natural compounds and therapeutic agents shouldn’t be disregarded, given its potential to hinder cancer cell proliferation as evident from clinical trials. Furthermore, enhancing EGCG’s bioavailability through its integration with other dietary components shows promise. To advance our understanding, future studies should meticulously investigate the intricate molecular mechanisms through which EGCG, either alone or in synergy with other therapeutic agents, effectively restrains the growth and progression of PCa. However, the primary hindrance to establishing EGCG as a potential candidate for cancer prevention and treatment remains the translation of laboratory findings from animal studies to human subjects.

Acknowledgments:
The authors would like to thank the Department of Science and Technology for providing the financial assistance.

Author's contributions:
SK Dhatwalia and M. Kumar designed the study and co-authored the manuscript. S Verma and S Rawat extracted the data from the studies. M. Kumar, S Verma and SK Dhatwalia wrote the manuscript. SK Dhatwalia and S Rawat edited the manuscript. All authors read and approved the final manuscript.

Ethical Committee:
Ethical Committee is not required for this study.

Informed Consent:
Informed Consent is not required for this study

Conflict of interest:
The authors declare that they have no conflict of interest

REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
2. Rawla P. Epidemiology of prostate cancer. World J Oncol 2019; 10: 63-89.
3. Ferlay J EM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I. Global cancer observatory: Cancer today. Lyon, France: International Agency for Research on cancer. Availability from: https://gco.iarc.fr/today, Accessed 02 February 2019.
4. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci - Landmark 2006; 11: 1388-1413.
5. Lan T, Park Y, Colditz GA, Liu J, Wang M, Wu K, Giovannucci E, Sutcliffe S. Adolescent dairy product and calcium intake in relation to later prostate cancer risk and mortality in the NIH-AARP diet and health study. Cancer Causes Control 2020; 31: 891-904.
6. Abdel-Rahman A, Anyangwe N, Carlacci L, Casper S, Danam RP, Enongene E, Erives G, Fabricant D, Gudi R, Hilmas CJ, Hines F. The safety and regulation of natural products used as foods and food ingredients. Toxicol Sci 2011; 123: 333-348.
7. Abdulrahman GO, Rahman GA. Epidemiology of breast cancer in Europe and Africa. J Cancer Epidemiol 2012; 2012: 1-5.
8. Saraon P, Drabovich AP, Jarvi KA, Diamandis EP. Mechanisms of androgen-independent prostate cancer. Ejifcc 2014; 25: 42.
9. Coletti R, Leonardelli L, Parolo S, Marchetti L. A QSP model of prostate cancer immunotherapy to identify effective combination therapies. Sci Rep 2020; 10: 9063.
10. Ravishankar B, Shukla VJ. Indian systems of medicine: a brief profile. Afr J Tradit Complement Altern Med 2007; 4: 319-337.
11. Mukhtar H, Ahmad N. Green tea in chemoprevention of cancer. Toxicol Sci 1999; 52: 111-117.
12. Chen DI, Dou QP. Tea polyphenols and their roles in cancer prevention and chemotherapy. Int J Mol Sci 2008; 9:1196-1206.
13. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009; 9: 429-439.
14. Kumar M, Sharma VL, Sehgal A, Jain M. Protective effects of green and white tea against benzo (a) pyrene induced oxidative stress and DNA damage in murine model. Nutr Cancer 2012; 64: 300-306.
15. Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med 1992; 21: 334-350.
16. Mukhtar H, Wang ZY, Katiyar SK, Agarwal R. Tea components: antimutagenic and anticarcinogenic effects. Prev Med 1992; 21: 351-360.
17. Stewart AJ, Mullen W, Crozier A. On-line high-performance liquid chromatography analysis of the antioxidant activity of phenolic compounds in green and black tea. Mol Nutr Food Res 2005; 49: 52-60.

18. Choi JY, Park CS, Kim DJ, Cho MH, Jin BK, Pie JE, Chung WG. Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. Neurotoxicology 2002; 23: 367-374.
19. Shimizu M, Shirakami Y, Moriwaki H. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci 2008; 9: 1034-1049.
20. Tachibana H. Molecular basis for cancer chemoprevention by green tea polyphenol EGCG. Forum Nutr 2009; 61: 156-169.
21. El-Mowafy AM, Al-Gayyar MM, Salem HA, El-Mesery ME, Darweish MM. Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling. Phytomedicine 2010; 17: 1067-1075.
22. Kim HS, Quon MJ, Kim JA. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. Redox Biol 2014; 2: 187-195.
23. Zhang Y, Wang X, Han L, Zhou Y, Sun S. Green tea polyphenol EGCG reverse cisplatin resistance of A549/DDP cell line through candidate genes demethylation. Biomed Pharmacother 2015; 69: 285-290.
24. Rangi S, Dhatwalia SK, Bhardwaj P, Kumar M, Dhawan DK. Evidence of similar protective effects afforded by white tea and its active component 'EGCG' on oxidative-stress mediated hepatic dysfunction during benzo (a) pyrene induced toxicity. Food Chem Toxicol 2018; 116: 281-291.
25. Yang CS, Wang ZY. Tea and cancer. J Natl Cancer Inst 1993; 85: 1038-1049.
26. Ahmad N, Feyes DK, Agarwal R, Mukhtar H, Nieminen AL. Green tea constituent epigallocatechin-3-gallate and induction of apoptosis and cell cycle arrest in human carcinoma cells. J Natl Cancer Inst 1997; 89: 1881-1886.
27. Yang GY, Liao J, Kim K, Yurkow EJ, Yang CS. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis 1998; 19: 611-616.
28. Ohishi T, Kishimoto Y, Miura N, Shiota G, Kohri T, Hara Y, Hasegawa J, Isemura M. Synergistic effects of (-)-epigallocatechin gallate with sulindac against colon carcinogenesis of rats treated with azoxymethane. Cancer Lett 2002; 177: 49-56.
29. Lambert JD, Hong J, Yang GY, Liao J, Yang CS. Inhibition of carcinogenesis by polyphenols: evidence from laboratory investigations. Am J Clin Nutr 2005; 81: 284S-291S.
30. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011; 82: 1807-1821.
31. Almatroodi SA, Almatroudi A, Khan AA, Alhumaydhi FA, Alsahli MA, Rahmani AH. Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant catechin in green tea, and its role in the therapy of various types of cancer. Molecules 2020; 25: 3146.
32. Ahmad N, Cheng P, Mukhtar H. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem Biophys Res Commun 2000; 275: 328-334.
33. Bhatia N, Agarwal R. Detrimental effect of cancer preventive phytochemicals silymarin, genistein and epigallocatechin 3-gallate on epigenetic events in human prostate carcinoma DU145 cells. The Prostate 2001; 46: 98-107.
34. Bhagat RM, Baruah RD, Safique S. Climate and tea [Camellia sinensis (L.) O. Kuntze] production with special reference to north eastern India: a review. J Environ Res Dev 2010; 4: 1017-1028.
35. Bose M, Lambert JD, Ju J, Reuhl KR, Shapses SA, Yang CS. The major green tea polyphenol,(-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat–fed mice. Journal Nutr 2008; 138: 1677-1683.
36. Bimonte S, Cascella M, Barbieri A, Arra C, Cuomo A. Shining a light on the effects of the combination of (–)-epigallocatechin-3-gallate and tapentadol on the growth of human triple-negative breast cancer cells. In Vivo 2019; 33: 1463-1468.

37. Bachmann SB, Frommel SC, Camicia R, Winkler HC, Santoro R, Hassa PO. DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells. Mol Cancer 2014; 13: 1-24.
38. Abd. Wahab NA, H. Lajis N, Abas F, Othman I, Naidu R. Mechanism of anti-cancer activity of curcumin on androgen-dependent and androgen-independent prostate cancer. Nutrients 2020; 12: 679.
39. Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I. Epigallocatechin-3-Gallate (EGCG) inhibits cell proliferation and migratory behaviour of triple negative breast cancer cells. J Nanosci Nanotechnol 2013; 13: 632-637.
40. Braun L, Daudt HM, Watson P. Overcoming the translational roadblocks: a cancer care and research model. Clin Transl Sci 2014; 3:1-7.
41. Bushman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer 1998; 31: 151-159.
42. Brody, H. Prostate Cancer. Nature 2015; 528: S117.
43. Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea—a review. J Am Coll Nutr 2006; 25: 79-99.
44. Baker KM, Bauer AC. Green tea catechin, EGCG, suppresses PCB 102-induced proliferation in estrogen-sensitive breast cancer cells. Int J Breast Cancer 2015; 2015: 1-7.
45. Cai YZ, Sun M, Xing J, Luo Q, Corke H. Structure–radical scavenging activity relationships of phenolic compounds from traditional Chinese medicinal plants. Life Sci 2006; 78: 2872-2888.
46. Chen J, Zhang L, Li C, Chen R, Liu C, Chen M. Lipophilized epigallocatechin gallate derivative exerts anti-proliferation efficacy through induction of cell cycle arrest and apoptosis on DU145 human prostate cancer cells. Nutrients 2019; 12: 92.
47. Chu LW, Ritchey J, Devesa SS, Quraishi SM, Zhang H, Hsing AW. Prostate cancer incidence rates in Africa. Prostate cancer 2011; 2011: 1-6.
48. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 34-45.
49. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003; 349: 366-381.
50. Clegg LX, Reichman ME, Miller BA, Hankey BF, Singh GK, Lin YD, Goodman MT, Lynch CF, Schwartz SM, Chen VW, Bernstein L. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: National Longitudinal Mortality Study. Cancer Causes Control 2009; 20: 417-435.
51. Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009; 33: 315-318.
52. Wheeler DS, Wheeler WJ. The medicinal chemistry of tea. Drug Dev Res 2004; 61: 45-65.
53. Botten D, Fugallo G, Fraternali F, Molteni C. Structural properties of green tea catechins. J Phys Chem B 2015; 119: 12860-12867.
54. Wang R, Zhou W, Jiang X. Reaction kinetics of degradation and epimerization of epigallocatechin gallate (EGCG) in aqueous system over a wide temperature range. J Agric Food Chem 2008; 56: 2694-2701.
55. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int J Cancer 2004; 108: 130-135.
56. Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007; 14: 78-85.
57. Connors SK, Chornokur G, Kumar NB. New insights into the mechanisms of green tea catechins in the chemoprevention of prostate cancer. Nutr Cancer 2012; 64: 4-22.
58. Yuan JM. Cancer prevention by green tea: evidence from epidemiologic studies. Am J Clin Nutr 2013; 98: 1676S-1681S.
59. Ito K. Prostate cancer in Asian men. Nat Rev Urol 2014; 11: 197-212.

60. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N, Mukhtar H. Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 2009; 15: 1947-1953.
61. Smith DM, Wang Z, Kazi A, Li LH, Chan TH, Dou QP. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med 2002; 8: 382-392.
62. Kazi A, Daniel KG, Smith DM, Kumar NB, Dou QP. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003; 66: 965-976.
63. Kazi A, Wang Z, Kumar N, Falsetti SC, Chan TH, Dou QP. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res 2004; 24: 943-954.
64. Khan N, Mukhtar H. Modulation of signaling pathways in prostate cancer by green tea polyphenols. Biochem Pharmacol 2013; 85: 667-672.
65. Dai W, Ruan C, Zhang Y, Wang J, Han J, Shao Z, Sun Y, Liang J. Bioavailability enhancement of EGCG by structural modification and nano-delivery: A review. J Funct Foods 2020; 65: 103732.
66. Zeng L, Ma M, Li C, Luo L. Stability of tea polyphenols solution with different pH at different temperatures. Int J Food Prop 2017 ; 20: 1-8.
67. Hara K, Ohara M, Hayashi I, Hino T, Nishimura R, Iwasaki Y, Ogawa T, Ohyama Y, Sugiyama M, Amano H. The green tea polyphenol (−)-epigallocatechin gallate precipitates salivary proteins including alpha-amylase: biochemical implications for oral health. Eur J Oral Sci 2012; 120: 132-139.
68. Gan RY, Li HB, Sui ZQ, Corke H. Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review. Crit Rev Food Sci Nutr 2018; 58: 924-941.
69. Nakagawa K, Miyazawa T. Chemiluminescence–high-performance liquid chromatographic determination of tea catechin,(−)-epigallocatechin 3-gallate, at picomole levels in rat and human plasma. Anal Biochem 1997; 248: 41-49.
70. Zagury Y, Kazir M, Livney YD. Improved antioxidant activity, bioaccessibility and bioavailability of EGCG by delivery in β-lactoglobulin particles. J Funct Foods 2019; 52: 121-130.
71. Takagaki A, Nanjo F. Metabolism of (−)-epigallocatechin gallate by rat intestinal flora. J Agric Food Chem 2010; 58: 1313-1321. 72. Schantz M, Erk T, Richling E. Metabolism of green tea catechins by the human small intestine. Biotechnol J 2010; 5: 1050-1059. 73. Sang S, Lambert JD, Ho CT, Yang CS. The chemistry and biotransformation of tea constituents. Pharmacol Res 2011; 64: 87-99.
74. Yong Feng W. Metabolism of green tea catechins: an overview. Curr Drug Metab 2006; 7: 755-809.
75. Meselhy MR, Nakamura N, Hattori M. Biotransformation of (-)-epicatechin 3-O-gallate by human intestinal bacteria. Chem Pharm Bull 1997; 45: 888-893.
76. Clifford MN, van der Hooft JJ, Crozier A. Human studies on the absorption, distribution, metabolism, and excretion of tea polyphenols. Am J Clin Nutr 2013; 98: 1619S-1630S.

77. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack T. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991; 63: 963-966.
78. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989; 64: 598-604.
79. Gupta S, Ahmad N, Nieminen AL, Mukhtar H. Growth inhibition, cell-cycle dysregulation, and induction of apoptosis by green tea constituent (-)-epigallocatechin-3-gallate in androgen-sensitive and androgen-insensitive human prostate carcinoma cells. Toxicol Appl Pharmacol 2000; 164: 82-90.
80. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234-1240.
81. Thakur VS, Gupta K, Gupta S. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases. Carcinogenesis 2012; 33: 377-384.

82. Berretta M, Francia RD. Focus on the use of green tea in cancer setting: between lights and shadows. WCRJ 2023; 10: e2581.
83. Allen NE, Sauvaget C, Roddam AW, Appleby P, Nagano J, Suzuki G, Key TJ, Koyama K. A prospective study of diet and prostate cancer in Japanese men. Cancer Causes Control 2004; 15: 911-920.
84. Henning SM, Wang P, Said JW, Huang M, Grogan T, Elashoff D, Carpenter CL, Heber D, Aronson WJ. Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate 2015; 75: 550-559.
85. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res 2009; 2: 673-682.
86. Mak JC. Potential role of green tea catechins in various disease therapies: progress and promise. Clin Exp Pharmacol Physiol 2012; 39: 265-273.
87. Hsieh TC, Wu JM. Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res 2009; 29: 4025-4032.
88. Posadino AM, Phu HT, Cossu A, Giordo R, Fois M, Thuan DT, Piga A, Sotgia S, Zinellu A, Carru C, Pintus G. Oxidative stress-induced Akt downregulation mediates green tea toxicity towards prostate cancer cells. Toxicol In Vitro 2017; 42: 255-262.
89. Yeo C, Han DS, Lee HJ, Lee EO. Epigallocatechin-3-gallate suppresses vasculogenic mimicry through inhibiting the twist/ VE-cadherin/AKT pathway in human prostate cancer PC-3 cells. Int J Mol Sci 2020; 21: 439.
90. Deb G, Shankar E, Thakur VS, Ponsky LE, Bodner DR, Fu P, Gupta S. Green tea–induced epigenetic reactivation of tissue inhibitor of matrix metalloproteinase-3 suppresses prostate cancer progression through histone-modifying enzymes. Mol Carcinog 2019; 58: 1194-1207.
91. Wang P, Wang B, Chung S, Wu Y, Henning SM, Vadgama JV. Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells. RSC Adv 2014; 4: 35242-35250.
92. Thomas F, Holly JM, Persad R, Bahl A, Perks CM. Green tea extract (epigallocatechin-3-gallate) reduces efficacy of radiotherapy on prostate cancer cells. Urology 2011; 78: 475-e15-21.
93. Posadino AM, Phu HT, Cossu A, Giordo R, Fois M, Thuan DT, Piga A, Sotgia S, Zinellu A, Carru C, Pintus G. Oxidative stress-induced Akt downregulation mediates green tea toxicity towards prostate cancer cells. Toxicol In Vitro 2017; 42: 255-262.
94. Vue B, Zhang S, Chen QH. Synergistic effects of dietary natural products as anti-prostate cancer agents. Nat Prod Commun 2015; 10: 2179-2188.
95. Pi M, Wu Y, Quarles LD. GPRC6A mediates responses to osteocalcin in β-cells in vitro and pancreas in vivo. J Bone Miner Res 2011; 26: 1680-1683.
96. Kim MH, Chung J. Synergistic cell death by EGCG and ibuprofen in DU-145 prostate cancer cell line. Anticancer Res 2007; 27: 3947-3956.
97. Yang J, Yu H, Sun S, Zhang L, Das UN, Ruan H, He G, Shen S. Mechanism of free Zn (2+) enhancing inhibitory effects of EGCG on the growth of PC-3 cells: interactions with mitochondria. Biol Trace Elem Res 2009; 131: 298-310.
98. Lane JA, Er V, Avery KN, Horwood J, Cantwell M, Caro GP, Crozier A, Smith GD, Donovan JL, Down L, Hamdy FC. ProDiet: a phase II randomized placebo-controlled trial of green tea Catechins and lycopene in men at increased risk of prostate cancer. Cancer Prev Res 2018; 11: 687-696.
99. Nair S, Barve A, Khor TO, Shen GX, Lin W, Chan JY, Cai L, Kong AN. Regulation of Nrf2-and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin 2010; 31: 1223-1240.

100. Ren F, Zhang S, Mitchell SH, Butler R, Young CY. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000; 19: 1924-1932.
101. Hagen RM, Chedea VS, Mintoff CP, Bowler E, Morse HR, Ladomery MR. Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells. Int J Cancer 2013; 43: 194-200.
102. Vayalil PK, Katiyar SK. Treatment of epigallocatechin-3-gallate inhibits matrix metalloproteinases-2 and-9 via inhibition of activation of mitogen-activated protein kinases, c-jun and NF-κB in human prostate carcinoma DU-145 cells. Prostate 2004; 59: 33-42.
103. Thomas F, Patel S, Holly JM, Persad R, Bahl A, Perks CM. Dihydrotestosterone sensitises LNCaP cells to death induced by epigallocatechin-3-gallate (EGCG) or an IGF-i receptor inhibitor. Prostate 2009; 69: 219-224.
104. Kumar NB, Pow-Sang J, Egan KM, Spiess PE, Dickinson S, Salup R, Helal M, McLarty J, Williams CR, Schreiber F, Parnes HL. Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention. Cancer Prev Res 2015; 8: 879-887.
105. Kumar NB, Pow-Sang J, Spiess PE, Park J, Salup R, Williams CR, Parnes H, Schell MJ. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins. Oncotarget 2016; 7: 70794-70802.
106. Henning SM, Wang P, Lee RP, Trang A, Husari G, Yang J, Grojean EM, Ly A, Hsu M, Heber D, Grogan T. Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer. Food Funct 2020; 11: 4114-4122.
107. Wang P, Aronson WJ, Huang M, Zhang Y, Lee RP, Heber D, Henning SM. Green tea polyphenols and metabolites in prostatectomy tissue: implications for cancer prevention. Cancer Prev Res 2010; 3: 985-993.